Spravato is a prescription medication (CIII Nasal Spray), for use in conjunction with an oral antidepressant. Spravato( esketamine), is an FDA approved medication used to treat Treatment- resistant depression.
SPRAVATO® nasal spray works differently than other medications to target depressive symptoms. SPRAVATO® targets the N-methyl-D-aspartate (NMDA) receptor. The exact way that SPRAVATO® works is unknown.
Contemporary oral antidepressants are widely understood to alleviate depression by elevating neurotransmitter levels in specific brain regions that influence mood. In contrast, Spravato focuses on the N-Methyl-D-Aspartate (NMDA) receptor, representing a departure from the mechanisms of action seen in currently prescribed oral antidepressants.
Esketamine, being the enantiomer of ketamine and an NMDA antagonist, operates by augmenting levels of the neurotransmitter glutamate and a growth factor known as BNDF.
Because of the risks for sedation, dissociation, and abuse and misuse, Spravato is only available through the restricted program called REMS. Spravato can only be administered at healthcare settings certified in the Spravato Rems program. It is used to closely monitor patients and maintain safety protocol.
The treatment plan typically involves an induction phase, where patients receive the nasal spray twice a week for 4 weeks, and a maintenance phase, where the frequency may be reduced.
Spravato is not a pain reliever or an aesthetic.
Side effects include dissociation, dizziness, nausea, sleepiness, feeling anxious, lack of energy, feeling very happy or excited. See the Spravato medication guide for complete safety information.
